Both Individual Investors Who Control a Good Portion of 3SBio Inc. (HKG:1530) Along With Institutions Must Be Dismayed After Last Week's 3.8% Decrease

Simply Wall StDec 19 17:18 ET

The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."

In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.

cls.cnDec 19 09:27 ET

3SBio Cancels All Treasury Shares

MT NewswiresDec 18 06:50 ET

3SBIO (01530.HK) canceled a total of 21.23 million shares of treasury stock.

Gelonghui, December 18, 3SBIO (01530.HK) announced that as of the date of this announcement, the company has repurchased a total of 21.23 million shares as treasury shares, accounting for approximately 0.89% of the total issued shares as of the date of this announcement (excluding treasury shares). These treasury shares have been canceled as of the date of this announcement.

Gelonghui FinanceDec 18 05:42 ET

Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.

The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.

Zhitong FinanceDec 16 01:21 ET

Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.

① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?

cls.cnDec 8 21:40 ET